Prognostic Significance of CD27 and CD56 on Newly Diagnosed MM Patients Treated with Bortezomib.
10.19746/j.cnki.issn.1009-2137.2021.03.027
- Author:
Cai-Xia ZHANG
1
;
Hong-Tao WANG
1
;
Guo-Jun ZHANG
2
Author Information
1. Department of Hematology, Shengjing Hospital of China Medical University, Shenyang 110021, Liaoning Province, China.
2. Department of Hematology, Shengjing Hospital of China Medical University, Shenyang 110021, Liaoning Province, China,E-mail: zhanggj@sj-hospital.org.
- Publication Type:Journal Article
- MeSH:
Bortezomib;
CD56 Antigen;
Hematopoietic Stem Cell Transplantation;
Humans;
Multiple Myeloma;
Prognosis;
Retrospective Studies
- From:
Journal of Experimental Hematology
2021;29(3):827-831
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the significance of CD27 and CD56 in the prognosis of multiple myeloma (MM) patients, and to establish a simple and convenient prognostic risk score.
METHODS:One hundred and eleven newly diagnosed MM patients treated by bortezomib in Shengjing hospital from January 1, 2013 to January 1, 2019 were selected, and the relationship between clinical characteristics and survival time of patients was analyzed.
RESULTS:The overall survival (OS) of patients in CD27
CONCLUSION:Among patients with MM treated by bortezomib, CD27
